Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured on The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, and its commercial product unbuzzd™. Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments.
The company is preparing for its upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients following Phase 1 testing in healthy volunteers. This trial represents a critical milestone for Quantum BioPharma as it advances its pipeline.
In addition to Lucid-MS, Durkacz highlighted unbuzzd™, a commercial alcohol metabolism product designed to accelerate blood alcohol metabolism and currently available in the U.S. market. Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness Inc., the company that markets unbuzzd™, and is entitled to royalty payments: 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The podcast appearance underscores Quantum BioPharma's dual focus on innovative therapies for neurodegenerative disorders and commercial health products. The company is dedicated to building a portfolio of assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.
For more details, the full press release is available at https://ibn.fm/HURxt. The latest news and updates relating to QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings.
